FLT3 and acute myeloid leukemia: The combination of gilteritinib with AZA and VEN in both the frontline and relapsed/refractory setting was studied in a phase I/II trial for FLT3-mutated AML, and it was found that the CR/CRi rate was 96% in the frontline cohort and 27% in the relapsed/refractory setting [32].